Retinoic acid (RA), 1 a derivative of vitamin A, serves as an important soluble factor that mediates the differentiation of both the neuronal and hematopoietic precursor cells. As a natural morphogen, RA specifies the axial patterning during the embryonic development and affects neurogenesis (1, 2) . RA is a powerful differentiating agent and induces the differentiation of many cell types such as epithelial cells and mesenchyme cells (3, 4) . It also induces the differentiation of cancer cells such as teratocarcinoma and leukemia (5) and many immortalized cell lines. Thus, RA has been used as an effective therapeutic agent for the treatment of acute promyelocytic leukemia (6) .
The human embryonal carcinoma cell line, NTera2 cl. D1 (NT2), has been extensively used as a model system to study growth and differentiation as well as cancer therapy. RA treatment induces growth arrest and terminal differentiation of NT2 cells into postmitotic central nervous system neurons (7, 8) . The RA-induced neuronal differentiation of NT2 cells is concomitant with the up-regulation of the homeotic genes, such as Hox 2.1 and Hox 2.2. On the contrary, the expression of growth factors, including transforming growth factor-␣ and basic fibroblast growth factor, and proto-oncogenes, such as c-myc and N-myc, are down-regulated during the neuronal differentiation (9) . These responses are mediated through two classes of nuclear receptors, the RA receptors and retinoid X receptors (10 -12) . Although it is well-documented that RA receptors and retinoid X receptors play essential roles in RAmediated events, including primitive endodermal differentiation, cell proliferation, and apoptosis, the molecular mechanisms underlying these diverse physiological actions have only recently been explored (13) (14) (15) (16) . Even less is known about how different genes are regulated by RA during these processes. The involvement of other signaling molecules, such as the coordinated regulation of the neurotrophin receptors, may mediate RA-induced central nervous system neuronal differentiation (17) . Thus, one major thrust has been the identification of genes that are regulated during the RA-mediated cellular events (18, 19) .
We have employed the RNA fingerprinting by arbitrarily primed PCR to identify candidate genes that are differentially regulated during the RA-induced neuronal differentiation of the NT2 cells (20) . Among the candidate genes identified, clone 8.31 encoded a novel gene that was downregulated during the RA-induced neuronal differentiation of NT2 cells. Here we report the cloning and characterization of this novel gene, designated RA-regulated nuclear matrix associated protein (Ramp). Ramp is a serine/threonine-rich protein that is associated with the nuclear matrix protein of the NT2 cells, and translocates from the nucleus to the cytoplasm during mitosis and cytokinesis. Our data suggest that Ramp plays a role in the cell proliferation of these human embryonal carcinoma cells.
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EXPERIMENTAL PROCEDURES
Cloning of Full-length cDNA of Ramp-Full-length cDNA of clone 8.31 (ramp) was obtained by screening an expression cDNA library prepared from undifferentiated NT2 cells (Stratagene) using the partial 8.31 cDNA fragment obtained by RNA fingerprinting by arbitrarily primed PCR as probes. The cDNA sequence encoding ramp has been submitted to GenBank™ (accession number AF345896). Radioactive cDNA probes were prepared using Megaprime DNA labeling system (Amersham Pharmacia Biotech) and hybridization was performed at 60°C. Single phages were obtained and transformed into XLOLR bacterial cells (Stratagene) and the cDNA fragment was cloned into pBK-CMV mammalian expression vector by in vivo excision.
Cell Culture and Cell Proliferation Assays-NT2 cells were cultured as previously described (21) . Cells were maintained in Opti-MEM I reduced-serum medium (Life Technologies, Inc.) supplemented with 5% fetal bovine serum (fetal bovine serum, Life Technologies, Inc.). NT2 cells were differentiated with 10 M all-trans RA (t-RA; Sigma Chemical Co.) in Dulbecco's modified Eagle's medium (high glucose formulation) supplemented with 10% fetal bovine serum. Cell synchronization was performed by treating NT2 cells with nocodazole (1 M) for 12 h, which arrested the cells at G 2 -M. Transfection of NT2 cells was performed using FuGENE reagent (Roche Molecular Biochemicals) in 96-well plates. Expression vectors (0.15 g) plus 0.05 g of the reference plasmid pCMV-␤gal, expressing ␤-galactosidase as internal control for normalization, were used. For cell proliferation assays, NT2 cells were transiently transfected with expression vectors containing wild type ramp, 6X histidine-, or EGFP-tagged ramp. Reference plasmid pCMV␤gal was co-transfected to serve as internal control for normalizing the transfection efficiency. MTT assays and ␤-galactosidase assays were performed as previously described (Roche Molecular Biochemicals) (22) . BrdUrd incorporation assays were performed using BrdUrd-based cell proliferation enzyme-linked immunosorbent assay (Roche Molecular Biochemicals). Briefly, cells were labeled with BrdUrd solution for 2 h at 37°C. The cells were then fixed and denatured using FixDenat solution. After incubation with horseradish peroxidase-conjugated antiBrdUrd solution for 2 h, the cells were washed and incubated with substrate solution. Absorbance was measured at 450 nm. All experiments were repeated at least three times.
Promoter Constructs and Alkaline Phosphatase Assays-Genomic DNA fragment (ϳ2396 bp) containing the putative ramp promoter and the first exon (2304 -2354 bp) of ramp cDNA (data not shown). The genomic DNA fragment was then fused to the 5Ј-end of the promoterless reporter secretory form of human placental alkaline phosphatase (SEAP, CLONTECH). Deletion mutant (Ramp⌬, ϳ311 bp) was constructed by deleting a ϳ2080-bp DNA fragment from the 5Ј-end of the putative promoter. For promoter analysis, a putative ramp promoter was subcloned to the 5Ј-region of the reporter gene SEAP. SV40 early and acetylcholine receptor ⑀ subunit promoters (23) were used as control in the experiment. NT2 cells transfected with promoter constructs were treated with 10 M t-RA in normal medium. After 24 h, transfected cells were lysed for luminescent SEAP and ␤-galactosidase assays (CLONTECH).
RNA Preparation, RT-PCR, and Northern Blot Analysis-Total RNA was prepared using TRIzol reagent (Life Technologies, Inc.) or as previously described (24) . Northern blot analysis was performed as previously described using ramp-specific cDNA probes at 60°C (25) .
Coupled in Vitro Transcription and Translation-Two micrograms of linearized plasmids were used for each coupled in vitro transcription/translation reaction using the TnT-coupled reticulocyte lysate system (Promega). Antisense ramp cDNA construct in the same expression vector was used as negative control; luciferase gene was employed as positive control.
Chromosomal Localization of Ramp by FISH-Genomic DNA-encoding ramp was labeled with digoxigenin dUTP by nick translation and was hybridized to normal metaphase chromosomes derived from PHAstimulated peripheral blood lymphocytes. After incubation with fluorescein-conjugated anti-digoxigenin antibodies, the cells were counterstained with DAPI. The location of ramp was labeled in green (indicated by white arrows). A biotin-labeled probe, which is specific for the heterochromatic region of chromosome 1, was co-hybridized with the genomic ramp clone. Chromosome 1-specific probes were detected by Texas avidin and was labeled in red (indicated by gray arrows).
Antibodies and Immunofluorescent Analysis-Cells were fixed with 4% paraformaldehyde (Fluka) in phosphate-buffered saline (PBS) and the immunofluorescent staining was performed. After blocking with 4% normal serum (Zymed Laboratories Inc.) in PBS containing 0.25% Triton-X (Roche Molecular Biochemical), and 2% bovine serum albumin (Sigma Chemical Co.), cells were incubated overnight at 4°C with primary antibodies diluted in antibody diluent (4% normal serum, 0.25% Triton-X, and 2% bovine serum albumin). Incubation with secondary antibodies was performed at room temperature for at least 2 h. Cells were visualized under a Zeiss Axiophot fluorescence microscope. Polyclonal antibodies were generated against peptides designed from the N and C termini of the translated Ramp amino acid sequence. Monoclonal antibodies detecting ␤-tubulin (Tub2.1) were obtained from Sigma Chemicals. Polyclonal antibodies specific for EGFP (CLON-TECH), 6ϫ histidine (CLONTECH), phospho-cdc2 Y15 (New England BioLab), and lamin A/C (Santa Cruz Biotechnology) were employed in the study. Alexa568-or Alexa488-conjugated secondary antibodies were obtained from Molecular Probes Inc.
Nuclear Matrix Preparation-High salt isolation of nuclear matrix was prepared according to He et al. (26) . NT2 cells were washed with ice-cold PBS and then extracted with cytoskeletal (CSK) buffer (10 mM PIPES, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EDTA, protease inhibitors, 1 mM phenylmethylsulfonyl fluoride, and 0.5% Triton-X) for 10 min at 4°C. The cytoskeletal fraction was collected by centrifugation, and the chromatin was solubilized by digestion with 1 mg/ml DNase I in CSK buffer for 15 min at 37°C. Ammonium sulfate was then added to a final concentration of 0.25 M, and samples were collected by centrifugation. High salt wash (2 M NaCl in CSK buffer) was performed for 5 min at 4°C. The final pellet (core nuclear matrix) was resuspended in 8 M urea.
Western Blot Analysis-Western blot analysis was performed as previously described (13) . Cells were washed twice with ice-cold PBS followed by a wash with ice-cold PBS supplemented with 1 mM sodium orthovanadate and protease inhibitor mixture (Complete, Roche Molecular Biochemicals). Cells were then lysed with lysis buffer (50 mM Tris-Cl at pH 8, 150 mM NaCl, 1% Triton-X, 1ϫ aprotinin; Sigma, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, and 1ϫ Complete) at 4°C for 15 min. Lysates were collected and centrifuged to remove cell debris. Protein assays were performed with the Bio-Rad Protein Assay kit based on the Bradford dye-binding procedure (BioRad). Protein samples (typically 40 g) were separated by SDS-polyacrylamide gel electrophoresis in 10% resolving gel using a Hoeffer minigel apparatus. Proteins were then electrotransferred to nitrocellulose membrane (Amersham Pharmacia Biotech). After blocking at room temperature for 1 h using TBS-Tween containing 5% non-fat milk, membranes were incubated overnight at 4°C with primary antibodies in TBS-Tween containing 5% non-fat milk. Membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies (1:2500, Zymed Laboratories Inc.) for 1 h at room temperature. After three washes with TBS-Tween, immunoreactive bands were detected using an ECL kit (Amersham Pharmacia Biotech) and visualized by x-ray film (Fuji).
RESULTS

Cloning of the Full-length Coding Sequence of Ramp-
The cDNA encoding full-length 8.31 (ramp) was obtained by screening a cDNA library prepared from the undifferentiated NT2 cells. Double-stranded sequencing by T7 DNA polymerase revealed that the cDNA (ϳ2831 bp) is novel in its gene identity. The full DNA sequence and its deduced amino acid sequence are shown in Fig. 1A . The cDNA contains a single open reading frame corresponding to a protein of 730 amino acids (ϳ79.4 kDa). The ATG codon preceded by a consensus Kozak sequence is found at position 124, and the TAG codon is found at position 2314. Hydropathy analysis of the predicted amino acid sequence reveals that the protein contains a high percentage of hydrophilic residues (Fig. 1B) . Although a potential transmembrane domain cannot be identified within the amino acid sequence, a putative nuclear localization signal is located at amino acid positions 197-203. The sequence is rich in serines and threonines (20.25% of all amino acids) and in basic residues (13.04% arginines, lysines, and histidines). There are five potential glycosylation sites at residues 190, 248, 289, 299, and 316, and three putative cAMP-and cGMP-dependent kinase phosphorylation sites at residues 413-416, 482-485, and 688 -691. Another interesting feature is the presence of a prolinerich motif that shares high homology with the SH3-binding consensus, PXXP, at residues 637-641. Moreover, there is a leucine zipper located at 577 and two WD repeats at 113 and 231 of the cloned ramp cDNA.
To confirm that the full-length cDNA encoded a functional protein, coupled in vitro transcription and translation was performed to estimate the molecular weight of the encoded protein. It was demonstrated that the cloned full-length ramp cDNA could be translated into a protein of ϳ85 kDa (Fig. 1C) . In addition, a chimeric enhanced green fluorescence protein (EGFP)-tagged Ramp protein (E-Ramp) was constructed by fusing the EGFP-encoding cDNA to the N terminus of the full-length ramp cDNA. The chimeric cDNA construct was transiently expressed in CHO cells and total proteins were collected. Immunoblotting using the anti-Ramp polyclonal antibodies revealed the expression of the EGFP-tagged Ramp proteins (Fig. 1D) . Two immunoreactive bands (ϳ110 and ϳ180 kDa) were observed, the identity of which was confirmed by immunoblotting with anti-EGFP antibodies. Because the Ramp protein contains several putative N-glycosylation sites, it is possible that the ϳ180-kDa immunoreactive represents the glycosylated protein.
Ramp Is Expressed in the Placenta and Testis-To obtain clues on the potential function(s) of ramp, we have examined the expression profile of ramp in both adult and fetal human tissues. Among the tissues examined, including brain, colon, heart, kidney, liver, lung, skeletal muscle, placenta, small intestine, spleen, stomach, and testis, two transcripts (ϳ5 and ϳ3 kb) of ramp were predominantly expressed in the placenta and testis ( Fig. 2A) . Interestingly, skeletal muscles also expressed low level of ramp (upon long exposure of the autoradiogram).
The expression of ramp was observed in all the human fetal tissues examined, which included brain, lung, liver, and kidney. All fetal tissues expressed the ϳ5-and ϳ3-kb ramp transcripts. Two extra transcripts of ϳ4 and ϳ2 kb were observed in the messenger RNA prepared from the fetal lung (Fig. 2B) . However, similar prominent expression of ramp was not observed in the corresponding adult tissues.
Based on abundant level of expression of ramp in fetal liver, dot blot analysis was performed to examine the mRNA level in hematopoietic tissues (Fig. 2C) . Although ramp was detected in all hematopoietic tissues examined, mRNA level was highest in thymus and bone marrow. A low level of ramp transcript was detected in the spleen and lymph node, and only a barely detectable level was observed in the peripheral leukocytes.
Chromosomal Localization of Ramp by Fluorescence in Situ Hybridization-DNA from a genomic clone of ramp was labeled with digoxigenin dUTP by nick translation. Labeled probe was combined with sheared human DNA and hybridized to normal metaphase chromosomes derived from PHA-stimulated peripheral blood lymphocytes. The initial experiment resulted in the specific labeling of the long arm of a group A chromosome, which was believed to be chromosome 1 on the basis of size, morphology, and banding pattern (Fig. 3A) . Thus, a biotinlabeled probe, which was specific for the heterochromatic region of chromosome 1, was co-hybridized with the genomic clone of ramp. The specific labeling of genomic fragment containing ramp was labeled green (indicated by white arrows), and the heterochromatin of the chromosome 1 labeled red (indicated by gray arrows) (Fig. 3B) . A total of 80 metaphase cells were analyzed with 76 exhibiting specific labeling. Measurements of 10 specifically labeled chromosomes 1 demonstrated that the genomic clone of ramp is located at a position that is 62% of the distance from the heterochromatic-euchromatic boundary of the telomere of chromosome arm 1q, an area that corresponds to band 1q32.1-32.2. The result is schematized in Fig. 3C .
RA Treatment Down-regulated the Expression of Ramp in NT2 Cells-To examine the regulation of ramp expression by RA, the full-length ramp cDNA was used as a probe to examine its change in expression profile upon treatment with RA for 0 -28 days (Fig. 4A) . Two transcripts (ϳ4.5 and ϳ3.5 kb) of ramp were detected in NT2 cells. The transcript expression of ramp was transiently up-regulated after 1 day of RA treatment, followed by a decrease, reaching a low level of expression at day 28. Moreover, total proteins were obtained from NT2 cells treated with t-RA for 6 or 12 days. An immunoprecipitation assay was performed using anti-Ramp (N terminus) antibodies. The resulted immunoprecipitates were electrophoresed and immunoblotted with anti-Ramp (C terminus) antibodies. As depicted in Fig. 4B , undifferentiated NT2 cells expressed abundant level of Ramp proteins, which was repressed after 6 days of RA treatment. Interestingly, additional immunoreactive bands (ϳ175 and ϳ180 kDa) were also detected by the anti-Ramp antibodies employed in the study. ϩ RNAs from human normal tissues (CLONTECH) was used in the dot blot to examine the expression of ramp in various adult tissues of hematopoietic origin, as well as fetal tissues.
FIG. 3. Chromosomal localization of ramp by FISH.
A, ramp genomic DNA probes labeled with digoxigenin dUTP were hybridized to normal metaphase chromosomes derived from PHA-stimulated peripheral blood lymphocytes. Positive signals were detected by incubation with fluorescent anti-digoxigenin antibodies and counterstained with DAPI. Specific labeling of the long arm of chromosome 1 was observed based on the size, morphology, and banding pattern. B, biotin-labeled probe specific for the heterochromatic region of chromosome 1 was co-hybridized with ramp. Heterochromatin was labeled with Texas red avidin in red (indicated in the black and white figure by gray arrows) and ramp in green (indicated by white arrows). Measurements of 10 specifically labeled chromosomes 1 demonstrated that ramp is located at a position, which is 62% of the distance from the heterochromaticeuchromatic boundary to the telomere of chromosome arm 1q, an area that corresponds to band 1q32.1-32.2. A total of 80 metaphase cells were analyzed with 76 exhibiting specific labeling. C, two ideograms illustrating the chromosomal position of ramp at 1q32.1-32.2. Both ideograms are from the International System for Human Cytogenetic Nomenclature 1995.
Ramp Is Localized to the Nucleus and Is a Nuclear Matrixassociated Protein-To define the subcellular localization of
Ramp protein, we transiently transfected the ramp expression vector into CHO cells. Transfected CHO cells were immunostained with anti-Ramp polyclonal antibodies and counterstained with DAPI. It was observed that the Ramp protein was localized to the nucleus (Fig. 5A) . A chimeric Ramp was constructed by fusing a 6X histidine tail to the C terminus of the Ramp. After transient transfection into CHO cells, the expression of Ramp was detected by double staining the transfected cells using the anti-6X histidine antibodies and anti-Ramp antibodies. Ramp protein was localized to the nuclear region of the transfected CHO cells, although some expression of Ramp could also be detected in the cytoplasm (Fig. 5B) . The nucleocytoplasmic trafficking of the transfected Ramp observed in CHO cells raised the possibility that Ramp is associated with the nuclear matrix.
To confirm that Ramp is a nuclear matrix-associated protein, we examined whether Ramp was localized to the nuclear matrix proteins of the NT2 cells. Nuclei were digested with DNase I and extracted with 2 M NaCl to enrich for the nuclear matrices and its associated proteins. The nuclear matrix preparations were then electrophoresed and immunoblotted with anti-Ramp antibodies. Ramp proteins were detected in the crude nuclear preparation as well as the DNase I-treated and NaCl-washed purified nuclear matrix proteins (Fig. 5C) .
Ramp Redistributes during the Cell Cycle of the NT2 CellsThe subcellular distribution of Ramp was then examined throughout the cell cycle of the unsynchronized NT2 cells. During the interphase, strong Ramp immunoreactivity was detected mainly in the nuclei of the NT2 cells (Fig. 6A) . Positive signal, although less concentrated, could also be observed in the cytoplasm. At pro-metaphase and metaphase, Ramp was excluded from the condensed chromosomes, with the staining localized to the cytoplasmic region. In telophase, the Ramp staining remained in the cytoplasmic region of the daughter cells. It is interesting to observe that Ramp became concentrated at the midzone as the dividing NT2 cells progressed to late anaphase in cytokinesis. The subcellular localization of Ramp during the cell cycle raises the possibility that Ramp is a nuclear matrix-associated protein and actively participates in the cell division of NT2 cells.
NT2 cells were then synchronized at G 2 -M phase by treatment with nocodazole. At pro-metaphase, NT2 cells revealed a strong DNA (DAPI) staining of the condensing chromosomes. Immunofluorescent staining using specific Ramp antibodies confirmed our previous observations with unsynchronized NT2 cells. Ramp proteins were localized to the cytoplasm and excluded from the chromatins (Fig. 6B) . The G 2 -M-arrested NT2 cells were then immunostained with control antibodies that detected the tyrosine-phosphorylated cdc2 (Phospho-cdc2 Y15). Interestingly, the subcellular distribution of phospho-cdc2 Y15 was similar to that of the Ramp proteins. Thus, the localization of the Ramp proteins is consistent with our hypothesis that Ramp actively participates in the process of cell division.
RA Could Up-regulate the Transcriptional Expression of Ramp in NT2 Cells-To evaluate the effect of RA on the expression of the ramp gene, we cloned and sequenced a ϳ2639-bp genomic DNA fragment containing the putative ramp promoter and the first exon (2304 -2354 bp) of ramp cDNA (data not shown). The genomic DNA fragment was then fused to the 5Ј-end of the promoterless reporter SEAP. The SV40 early and the acetylcholine receptor ⑀ promoters (AChR⑀) (23) were used as control promoter reporter plasmids in the study. Transient transfection into NT2 cells resulted in the constitutive expression of SEAP, demonstrating that the putative ramp promoter was transcriptionally active in undifferentiated NT2 cells. The transfected NT2 cells were treated with 10 M t-RA for 24 h, and the SEAP expression was monitored. RA up-regulated the relative expression of SEAP by ϳ40% (p Ͻ 0.005; Fig. 7A ). This is consistent with our previous observations that the expression of ramp was transiently up-regulated during the early stage of neuronal differentiation. Deletion of the 2080-bp DNA fragment from the putative ramp promoter (Ramp⌬) reduced the expression level of the reporter SEAP as well as the induction by RA. Similarly, RA treatment did not significantly affect the expression level of the control SV40 early and AChR⑀ promoters.
As the first step to explore the possibility that Ramp might play a role in the cell proliferation of the NT2 cells, we examined the effect of short term RA treatment on the proliferation of NT2 cells. NT2 cells were treated with t-RA (10 M) for 1-7 days. The cell proliferation was quantitated by measuring the metabolic rate of viable cells and by determining the total cell count of NT2 cells. When NT2 cells were treated with t-RA for 1 day, there was a significant increase in the proliferation of NT2 cells, both in terms of metabolic activities (ϳ12%, Fig. 7B ), as well as in total cell number (ϳ18.9%, Fig. 7C ). At day 2, significant difference between the RA treatment or the control solvent treatment was not observed. This was followed by a sharp decrease in the total metabolic rate at day 4 of RA treatment. To further confirm the effect of RA on the proliferation of NT2 cells, we examined the rate of cell proliferation by monitoring the BrdUrd incorporation after 1-3 days of RA treatment. As shown in Fig. 7D , the rate of BrdUrd incorporation was increased by more than 10% of the control after 1 day of RA treatment. Similar down-regulation was observed after day 2 of RA treatment. Thus, our data demonstrated a good correlation between the expression of ramp and the cell proliferation rate of NT2 cells .   FIG. 4 . RA treatment down-regulated the expression of Ramp in NT2 cells. A, Northern blot analysis of ramp expression during the RA-induced neuronal differentiation of NT2 cells. Total RNA (10 g) prepared from NT2 cells treated with t-RA for 0 -28 days was hybridized with the full-length ramp cDNA at high stringency. The position of the 28 S ribosomal RNAs is indicated, whereas arrowheads depict the positions of the ramp transcripts. B, total protein lysates were obtained from NT2 cells either treated with t-RA or control solvent for 6 or 12 days. Antibodies specific to the N terminus (N) were added, and the immunoprecipitates were electrophoresed. Immunoblotting was performed using antiRamp (C terminus specific; C) antibodies.
Overexpression of Ramp Enhanced the Cell Proliferation of NT2
Cells-To further evaluate the effect of ramp on the cell proliferation, we transiently transfected the ramp expression vector into the NT2 cells. Control ␤-galactosidase expression vector driven by the constitutively expressed CMV promoter was used for normalizing the transfection efficiency. Rate of cell proliferation was monitored by MTT assays 48 h after transfection. Overexpression of ramp significantly up-regulated the proliferation rate of the NT2 cells by ϳ10% (Fig. 8A) . We could observe similar up-regulation of cell proliferation rate (ϳ14%) when the human neuroblastoma SY5Y cells were transfected transiently with the wild type ramp (Fig. 8B) .
The effect of ramp on the proliferation of NT2 cells was also monitored by the BrdUrd incorporation assays. We transiently transfected the EGFP-tagged ramp (E-Ramp) expression vector into the NT2 cells and examine the rate of BrdUrd incorporation. Because the expression of retinoid receptor (RXR␣) was not affected during the early stage of RA treatment (13), EGFPtagged RXR␣ (E-RXR) was used as negative control in the experiment. Overexpression of E-Ramp significantly up-regulated the NT2 cell proliferation rate by ϳ30% whereas transient transfection of E-RXR did not significantly affect the NT2 cell proliferation rate (Fig. 8C ).
DISCUSSION
In this paper, we report the identification and characterization of a novel gene, designated ramp. This gene was initially identified as a candidate gene that was down-regulated during the RA-induced neuronal differentiation of human NT2 cells. Cloning of the full-length cDNA reveals that Ramp does not share any homology with known proteins, and that it is a serine/threonine-rich protein expressed predominantly in adult placenta, testis, and hematopoietic tissues such as thymus and bone marrow. We demonstrate that Ramp associates with the nuclear matrix in the undifferentiated NT2 cells. Furthermore, the distinct subcellular localization of Ramp during the cell cycle, together with its capabilities to enhance the cell proliferation, suggests a role for Ramp in the mitosis and cytokinesis of the NT2 cells.
The deduced amino acid sequence of Ramp exhibits a number of interesting features. Although Ramp contains a putative nuclear localization signal, prediction based upon the amino acid composition using PSORT server reveals that Ramp can both be a cytoplasmic and nuclear protein. Another interesting feature is the proline-rich motif, conforming to the SH3-binding consensus PXXP (27) . The sequence TLPLPLRP shares high homology with the proline-rich domain of yet another serine/ threonine-rich protein, Sirm (28) . In addition, Ramp contains an LXXLL motif. The LXXLL motif is demonstrated to be essential for the association of thyroid hormone receptor-binding protein to the liganded thyroid hormone receptor and retinoic acid receptor (29) . It is well known that cellular communication is made possible in part by the post-translational modification of the signaling proteins. With serine and threonine residues constituting more than 20% of the Ramp protein, Ramp may serve different functions depending on the phosphorylation status. We have observed that Ramp proteins are phosphorylated at serine in undifferentiated NT2 cells (data not shown). This suggests that phosphorylation of Ramp may involve protein kinases, such as Akt, RSK1, and p70S6K (30) . However, its potential signaling kinases and phosphatases remain to be identified. The presence of two WD repeats in Ramp is also of interest. WD repeats were first identified in the ␤-subunit of heterotrimeric GTP-binding proteins (G proteins) (31) . The role of WD repeats in facilitating protein-protein interaction has been proposed (32) . It is noteworthy that many of these mammalian WD repeat-containing proteins, such as chromatin assembly factor I, retinoblastoma-binding proteins, and Cdc20/fizzy, are involved in cell cycle regulation (32) (33) (34) . Our preliminary data on the analysis of ramp promoter suggest that the transcriptional expression of ramp in NT2 cells is up-regulated during the early phase of RA treatment. Moreover, our data further demonstrate that the essential regulatory elements are located in the 2102-bp DNA fragment of the putative ramp promoter. However, the detailed regulatory mechanism of the ramp expression still remains unknown and awaits to be determined. Subcellular localization of Ramp provides insight into the potential functions of Ramp. Although low expression of Ramp is detected in the cytoplasm, it is more condensed to the nuclei of the undifferentiated NT2 cells. In actively dividing cells, as revealed by the DAPI counterstain, higher expression of Ramp is observed and localized in the cytoplasmic region of the NT2 cells. The subcellular distribution of Ramp suggests its possible role as a nuclear matrix-associated protein, which is the set of proteins that resists the nuclease treatment, as well as the high salt treatment (26) . In light of the fact that the nuclear matrixassociated proteins normally redistribute during the mitosis and cytokinesis (35), we have observed that Ramp is concentrated at the midzone of the late telophase NT2 cells, consistent with a potential role of Ramp in cytokinesis. During cytokinesis, daughter cells are cleaved in two by the constriction of an actin-rich contractile ring, which encircles the equator of the dividing cells. Myosin II present in the contractile ring is essential for the constriction of the furrow (36) . In this midzone, the microtubule bundle between the chromosomes of the daughter cells and assemble with other midzone-associated proteins, such as kinesin, and inner centromere protein, to form the midbody (37) . These structures strongly affect the proper completion of cytokinesis, thus requiring an accurate assembly of the midzone proteins. When NT2 cells are arrested at the pro-metaphase (G 2 -M) by nocodazole, Ramp becomes FIG. 7 . RA transiently up-regulated the transcriptional expression of ramp promoter and the cell proliferation of NT2 cells. A, Ramp promoter vectors were constructed by subcloning the upstream genomic DNA fragment of ramp to the 5Ј-end of the SEAP reporter gene. Ramp deletion promoter vector (Ramp⌬) was constructed by deleting a 2080-bp DNA fragment from the 5Ј-end of the putative ramp promoter. SV40 early and AChR⑀ promoters were used as control in the study. Promoter vectors were transiently transfected into the NT2 cells. The efficiency of transfection was normalized using a ␤-galactosidase expression vector in each transfection. The cells were lysed after 24-h treatment with t-RA (10 M). Alkaline phosphatase and ␤-galactosidase assays were performed. Bars show mean Ϯ S.E.; n ϭ 5. B, NT2 cells were treated with t-RA (10 M) for 1-7 days. MTT assays were performed on days 1, 2, 4, and 7 as described. C, NT2 cells were trypsinized and counted using a Coulter cell counter on the days as indicated. D, NT2 cells were treated with t-RA (10 M) for 1-3 days. BrdUrd assays were performed as described. For B to D, the mean absorbance obtained using solvent control was designated as 100%. Results shown represent the mean Ϯ S.E. of a typical experiment; n ϭ 6. The mean is shown as: *, p Ͻ 0.005, unpaired Student's t test, compared with the control. totally excluded from the condensed chromosomal DNA. During the progression into mitosis, the phospho-cdc2 Y15 is activated by the cdc25 phosphatase by dephosphorylating the cdc2 (38) . Interestingly, we have demonstrated that the subcellular distribution of Ramp is in close association with the phosphocdc2, which signifies the progression of the NT2 cells into mitosis. The precise interplay between the cyclins, Ramp, and the progression of the cell cycle, however, remains to be elucidated.
The functional role of nuclear matrix has been controversial. Until recently, nuclear matrix-associated proteins, such as ATRX and AKAP95, are demonstrated to be associated with an X-linked mental retardation syndrome and anchors the protein kinase A during the mitosis, respectively (39, 40) . In this study, we have demonstrated a close association of ramp expression with the rate of proliferation of NT2 cells. The transient upregulation of ramp observed at day 1 of RA treatment can be explained by the up-regulation of cell proliferation rate during the first day of RA treatment. Prolonged RA treatment reduced the NT2 cell proliferation rate, coincidental with the decrease in the expression of ramp. This is further supported by the observation that the proliferation rate of NT2 cells can be induced by the transient overexpression of ramp. Although ramp was originally identified in the human EC cells, its transcriptional expression is also down-regulated in a number of RA-responsive leukemia cell lines 2 . The strong association of ramp with early embryonic development is exemplified by the high expression of ramp in the fetal tissues such as brain, lung, liver and kidney, but not in the adult tissues. Taken together with its restrictive expression pattern in the adult tissues, it is possible that Ramp might play different role during the embryogenesis, and in the functioning of specific adult tissues. The differential roles of Ramp may be mediated by the presence of different ramp isoforms, the expression of which can be regulated during development.
The gene encoding Ramp was localized to the chromosome 1q32.1-32.2. Chromosome 1q32 has been mapped to several genetic diseases including the complement system malfunctioning, as well as the Usher disease, which is characterized by a combined loss of both the hearing and visual systems (41) . Another gene located in this region is a phosphoprotein known as Mitosin. Similar to Ramp, Mitosin is also suggested to involve in the cell cycle progression (42) . Moreover, the Alzheimer's disease is also mapped to the region of 1q32, although the exact position remains to be elucidated. Hence, it will be of great interest to examine whether ramp is involved in any of these genetic diseases.
In summary, we have cloned and characterized a novel gene, ramp, which is regulated during the RA-induced neuronal differentiation of NT2 cells. Ramp is a serine/threoninerich protein associated with the nuclear matrix of NT2 cells. While the immunocytochemical study suggests its role in the cell cycle, promoter analysis, overexpression studies and cell proliferation assays support its role in the cell proliferation of NT2 cells. The mapping of ramp to the chromosome 1q32.1-2 also suggests that it may potentially be involved in genetic diseases such as the complement malfunctioning and Usher disease.
